Adapalene and benzoyl peroxide gel is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. The gel combines adapalene, a retinoid, with benzoyl peroxide, an oxidizing agent, to treat acne.
Pharmacokinetic Data
A pharmacokinetic study involving 10 adult subjects with acne vulgaris demonstrated adapalene C max of 0.21 ng/mL and AUC 0-24h of 1.99 ng•h/mL, with excretion primarily via the biliary route. Benzoyl peroxide is absorbed through the skin and converted to benzoic acid, eliminated in the urine.
Clinical Assessment
Clinical studies assessed the gel’s efficacy in 517, 1668, and 285 subjects aged 9 to 11 years, respectively, comparing it to vehicle gel. At baseline, subjects had between 20 and 50 inflammatory lesions and 30 to 100 non-inflammatory lesions, with a majority exhibiting a ‘Moderate’ Investigator Global Assessment score. Treatment response, defined as a two grade improvement and ‘Clear’ or ‘Almost Clear’ rating at Week 12, was evaluated using the Investigator’s Global Assessment (IGA) and lesion counts. An IGA score of ‘Clear’ corresponded to residual hyperpigmentation and erythema, while ‘Almost Clear’ indicated the presence of scattered comedones and small papules. The gel was applied once daily after washing, using a pea-sized amount for affected areas, avoiding the eyes, lips, and mucous membranes. The studies utilized a 12-week duration.